Physicians should also carefully explain to the patients the potential benefits and some adverse reactions, such as dyspepsia with dabigatran, associated with these new oral agents and the ...

A new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without leaving ...

Lixiana is a once-daily selective Factor Xa inhibitor and is the fourth entrant in a relatively new category of novel oral anticoagulants (NOACs) that offer advantages over older drugs such as ...

The bonds holding the two peptides together can be broken on demand, providing the anticoagulant ingredient with its own on-off switch. This new drug-discovery approach is a potential game-changer ...

Gilead ends $785M Yuhan deal for small-molecule MASH drugs BioWorld Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic ...

These two classes of medications serve completely different purposes. Anticoagulants are used to prevent new and future cases of blood clots that can lead to PE. They may also reduce the size of a ...

Are you searching for effective medications to treat 'Anticoagulants'? This comprehensive guide provides the latest information on medications-both generic and branded-that are essential for ...

a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate ...

The rejection of the drug, marketed as AndexXa in the US, means that Boehringer Ingelheim’s Pradaxa (dabigatran) remains the only new anticoagulant on the market with a reversal agent available.

Tom Nolan reviews this week’s research Trials of direct oral anticoagulants for atrial fibrillation have excluded patients with acute ischaemic stroke because of concerns over the risk of haemorrhagic ...

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...